318 related articles for article (PubMed ID: 32270928)
21. Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.
Arzt M; Gao B; Mozneb M; Pohlman S; Cejas RB; Liu Q; Huang F; Yu C; Zhang Y; Fan X; Jenkins A; Giuliano AE; Burridge PW; Cui X; Sharma A
Stem Cell Reports; 2023 Oct; 18(10):1913-1924. PubMed ID: 37657447
[TBL] [Abstract][Full Text] [Related]
22. Automated image analysis system for studying cardiotoxicity in human pluripotent stem cell-Derived cardiomyocytes.
Cao L; der Meer ADV; Verbeek FJ; Passier R
BMC Bioinformatics; 2020 May; 21(1):187. PubMed ID: 32408861
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes].
Kurokawa J; Shimizu S; Sakamoto K
Yakugaku Zasshi; 2024; 144(3):251-255. PubMed ID: 38432933
[TBL] [Abstract][Full Text] [Related]
25. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
[TBL] [Abstract][Full Text] [Related]
26. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
27. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
[TBL] [Abstract][Full Text] [Related]
29. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
[TBL] [Abstract][Full Text] [Related]
30. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives].
Yanagida S; Kawagishi H; Kanda Y
Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924
[TBL] [Abstract][Full Text] [Related]
31. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
32. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
[TBL] [Abstract][Full Text] [Related]
33. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
35. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
36. Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment.
Goßmann M; Linder P; Thomas U; Juhasz K; Lemme M; George M; Fertig N; Dragicevic E; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2020 Sep; 105():106892. PubMed ID: 32629160
[TBL] [Abstract][Full Text] [Related]
37. Single-Cell Transcriptomics of Engineered Cardiac Tissues From Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Abnormal Developmental Trajectory and Intrinsic Contractile Defects in Hypoplastic Right Heart Syndrome.
Lam YY; Keung W; Chan CH; Geng L; Wong N; Brenière-Letuffe D; Li RA; Cheung YF
J Am Heart Assoc; 2020 Oct; 9(20):e016528. PubMed ID: 33059525
[TBL] [Abstract][Full Text] [Related]
38. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
[TBL] [Abstract][Full Text] [Related]
39. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts.
Rodriguez ML; Graham BT; Pabon LM; Han SJ; Murry CE; Sniadecki NJ
J Biomech Eng; 2014 May; 136(5):051005. PubMed ID: 24615475
[TBL] [Abstract][Full Text] [Related]
40. Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues.
Xu H; Liu G; Gong J; Zhang Y; Gu S; Wan Z; Yang P; Nie Y; Wang Y; Huang ZP; Luo G; Chen Z; Zhang D; Cao N
Adv Sci (Weinh); 2022 Oct; 9(30):e2203388. PubMed ID: 36055796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
